loading
Lyell Immunopharma Inc stock is traded at $1.105, with a volume of 459.97K. It is up +0.45% in the last 24 hours and down -5.56% over the past month. Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$1.10
Open:
$1.12
24h Volume:
459.97K
Relative Volume:
0.43
Market Cap:
$307.14M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-1.3155
EPS:
-0.84
Net Cash Flow:
$-159.01M
1W Performance:
-8.68%
1M Performance:
-5.56%
6M Performance:
-59.67%
1Y Performance:
-43.04%
1-Day Range:
Value
$1.09
$1.16
1-Week Range:
Value
$1.06
$1.20
52-Week Range:
Value
$0.85
$3.2556

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name
Name
Lyell Immunopharma Inc
Name
Phone
650 695-0677
Name
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
Employee
224
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
LYEL's Discussions on Twitter

Compare LYEL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LYEL 1.105 307.14M 54,000 -210.26M -159.01M -0.84
VRTX 467.31 119.83B 10.63B -479.80M -1.35B 13.33
REGN 761.30 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 566.22 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.69 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.64 24.08B 3.30B -501.07M 1.03B 11.54

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-14-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-11-22 Downgrade Goldman Buy → Neutral
Oct-17-22 Initiated H.C. Wainwright Buy
Jul-12-21 Initiated BofA Securities Buy
Jul-12-21 Initiated Goldman Buy
Jul-12-21 Initiated JP Morgan Overweight
Jul-12-21 Initiated Morgan Stanley Overweight
View All

Lyell Immunopharma Inc Stock (LYEL) Latest News

pulisher
Nov 15, 2024

Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know - MSN

Nov 15, 2024
pulisher
Nov 12, 2024

HC Wainwright Reiterates "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts - Benzinga

Nov 12, 2024
pulisher
Nov 09, 2024

Lyell Immunopharma: Q3 Earnings Snapshot - AOL

Nov 09, 2024
pulisher
Nov 08, 2024

Lyell Immunopharma Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 - GlobeNewswire

Nov 07, 2024
pulisher
Nov 06, 2024

Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Lyell's Novel CAR T-Cell Therapy Data to Be Unveiled at ASH 2024 Following FDA Fast Track Status | LYEL Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Reduction in Lyell Immunopharma I - GuruFocus.com

Nov 05, 2024
pulisher
Nov 03, 2024

Lyell shares down as BofA double downgrades to Sell - MSN

Nov 03, 2024
pulisher
Nov 03, 2024

Lyell Immunopharma (NASDAQ:LYEL) Downgraded to “Underperform” Rating by Bank of America - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

Lyell Immunopharma acquires ImmPACT Bio to boost CAR T-cell therapy - Investing.com India

Nov 01, 2024
pulisher
Oct 31, 2024

Lyell Immunopharma Completes Acquisition of ImmPACT Bio - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

B of A Securities Downgrades Lyell Immunopharma (LYEL) - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Lyell Immunopharma’s (LYEL) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy - Benzinga

Oct 30, 2024
pulisher
Oct 30, 2024

Lyell shares down as BofA double downgrades to Sell By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

Lyell cut to underperform by BofA, pipeline reorganization cited - MSN

Oct 30, 2024
pulisher
Oct 30, 2024

Lyell Immunopharma (NASDAQ:LYEL) Lowered to Underperform Rating by Bank of America - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

HC Wainwright Reiterates Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Lyell Immunopharma shares maintain neutral rating on acquisition By Investing.com - Investing.com UK

Oct 28, 2024
pulisher
Oct 27, 2024

Lyell Immunopharma’s Acquistion of ImmPACT Bio USA - Global Legal Chronicle

Oct 27, 2024
pulisher
Oct 25, 2024

Lyell Will Seek To Improve On Existing CAR-Ts Via Merger With ImmPACT - Citeline News & Insights

Oct 25, 2024
pulisher
Oct 25, 2024

Lyell Immunopharma stock hits 52-week low at $1.05 By Investing.com - Investing.com Australia

Oct 25, 2024
pulisher
Oct 25, 2024

Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline - Pharmaceutical Technology

Oct 25, 2024
pulisher
Oct 25, 2024

Lyell Immunopharma stock hits 52-week low at $1.05 - Investing.com

Oct 25, 2024
pulisher
Oct 25, 2024

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth (NASDAQ:LYEL) - Seeking Alpha

Oct 25, 2024
pulisher
Oct 24, 2024

Lyell, in search of a turnaround, to buy cell therapy startup ImmPact - BioPharma Dive

Oct 24, 2024
pulisher
Oct 24, 2024

Lyell boosts pipeline with ImmPACT acquisition - Investing.com India

Oct 24, 2024
pulisher
Oct 24, 2024

Lyell Immunopharma to Buy ImmPact; Refocuses Pipeline on T-Cell Cancer Treatments - MarketWatch

Oct 24, 2024
pulisher
Oct 24, 2024

Lyell Immunopharma to acquire ImmPACT Bio (NASDAQ:LYEL) - Seeking Alpha

Oct 24, 2024
pulisher
Oct 24, 2024

Lyell boosts pipeline with ImmPACT acquisition By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 24, 2024

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes - GlobeNewswire

Oct 24, 2024

Lyell Immunopharma Inc Stock (LYEL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):